克隆性免疫球蛋白重链基因重排检测可以作为诊断恶性B细胞性非霍奇金淋巴瘤的有效分子标志。
Clonal immunoglobulin heavy chain gene rearrangement can be used as a effective diagnostic molecular marker for B-NHL.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。
The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma, which is a type of non-Hodgkin's lymphoma.
组织学形态均为恶性弥漫性非霍奇金淋巴瘤，免疫表型B细胞来源9例，T细胞来源1例。
Histologicallly, all cases were diffuse non - Hodgkin lymphoma. 9 cases were B and 1 case were t immunophenotype.
组织学形态均为恶性弥漫性非霍奇金淋巴瘤，免疫表型B细胞来源9例，T细胞来源1例。
Histologicallly, all cases were diffuse non - Hodgkin lymphoma. 9 cases were B and 1 case were t immunophenotype.
应用推荐